|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 35/12 | (2015.01) |
| A61K 38/014 | (2013.01) | ||
| A61F 2/02 | (2006.01) | ||
| A61K 35/28 | (2013.01) | ||
| A61K 35/30 | (2013.01) | ||
| C12N 15/09 | (2006.01) | ||
| A61K 35/32 | (2013.01) | ||
| A61K 38/01 | (2006.01) | ||
| A61L 27/36 | (2006.01) | ||
| A61K 35/34 | (2013.01) | ||
| A61L 27/38 | (2006.01) | ||
| A61K 35/35 | (2013.01) | ||
| A61K 35/28 | (2015.01) | ||
| A61K 35/36 | (2013.01) | ||
| A61K 35/30 | (2015.01) | ||
| A61K 35/38 | (2013.01) | ||
| A61K 35/32 | (2015.01) | ||
| A61K 35/44 | (2013.01) | ||
| A61K 35/34 | (2015.01) | ||
| A61K 35/52 | (2013.01) | ||
| C12N 5/069 | (2013.01) | ||
| A61K 35/35 | (2015.01) | ||
| C12N2501/60 | (2013.01) | ||
| A61K 35/36 | (2015.01) | ||
| A61K 35/38 | (2015.01) | ||
| C12N2510/00 | (2013.01) | ||
| A61K 35/44 | (2015.01) | ||
| C12N2533/54 | (2013.01) | ||
| A61K 35/52 | (2015.01) | ||
| A61L 27/3633 | (2013.01) | ||
| C12N 5/071 | (2010.01) | ||
| A61L 27/3808 | (2013.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61P 9/00 | (2018.01) |
| (11) | Number of the document | 3233094 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15871199.4 |
| Date of filing the European patent application | 2015-12-18 | |
| (97) | Date of publication of the European application | 2017-10-25 |
| (45) | Date of publication and mention of the grant of the patent | 2025-01-08 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/066782 |
| Date | 2015-12-18 |
| (87) | Number | WO 2016/100869 |
| Date | 2016-06-23 |
| (30) | Number | Date | Country code |
| 201462094915 P | 2014-12-19 | US |
| (72) |
GINSBERG, Michael, Daniel , US
NOLAN, Daniel, Joseph , US
DAVIS, Claude, Geoffrey , US
|
| (73) |
Angiocrine Bioscience, Inc. ,
3570 Carmel Mountain Road
Suite 200, San Diego, CA 92130,
US
|
| (54) | BIOCOMPATIBLE IMPLANTS COMPRISING ENGINEERED ENDOTHELIAL CELLS |
| BIOCOMPATIBLE IMPLANTS COMPRISING ENGINEERED ENDOTHELIAL CELLS |